Evidence map›Paper›PMID 40375441›Full record

ArticleBritish journal of haematology2025

Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis.

Amal Haujir, Michael Tøstesen, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen, Jørn Starklint, Christian Bjørn Poulsen, Pär Lars Josefsson, Erik Clasen-Linde, Michael Pedersen, Andriette Dessau-Arp and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amal HaujirDepartment of Hematology, Sygehus Lillebælt, Vejle, Denmark.
Michael TøstesenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0009-0009-1420-7997
Tarec Christoffer El-GalalyDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Thomas Stauffer LarsenDepartment of Hematology, Odense Universitetshospital, Odense, Denmark.ORCID https://orcid.org/0000-0002-8418-6708
Jørn StarklintDepartment of Hematology, Hospitalesenheden Vest, Gødstrup, Denmark.
Christian Bjørn PoulsenDepartment of Hematology, Sjællands Universitetshospital, Roskilde, Denmark.
Pär Lars JosefssonDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Erik Clasen-LindeDepartment of Hematology, Sydvestjysk Sygehus, Esbjerg, Denmark.
Michael PedersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Andriette Dessau-ArpDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Michael Roost ClausenDepartment of Hematology, Sygehus Lillebælt, Vejle, Denmark.
Judit Mészáros JørgensenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibodiesantibody therapymalignant lymphomas

Identifiers

PMID40375441
PMCPMC12234280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.